Trials / Active Not Recruiting
Active Not RecruitingNCT06773455
Tralokinumab for Dupilumab Failures
A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on Dupilumab
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tralokinumab | 600mg at week 0 followed by 300mg Q2W for 24 weeks |
Timeline
- Start date
- 2023-09-11
- Primary completion
- 2025-02-01
- Completion
- 2025-04-01
- First posted
- 2025-01-14
- Last updated
- 2025-01-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06773455. Inclusion in this directory is not an endorsement.